Translations of Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia

LanguageTitleStatusOperations
Danishn/aNot translated
Dutchn/aNot translated
English (source)Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from RussiaPublished
Frenchn/aNot translated
Germann/aNot translated
Italiann/aNot translated
Spanishn/aNot translated
Swahilin/aNot translated
Swedishn/aNot translated